Pharmacovigilance

#AI #Biopharmaceuticals #Lab automation #Machine learning #Pharmacovigilance

AE reporting turnarounds and the translation issue 

Listen to this article on the DDW Podcast:   The workload in pharmacovigilance (PV) is soaring and as new vaccines and medications enter the market, it’s crucial to track adverse events (AE). As AE reports still have to be filed within 24 hours, Kathleen O’Brien of Amplexor Life Sciences lays out a blueprint for centralising global AE… Read More

#Editor's Choice #Exclusive Content #News #Regulatory

#Automation / robotics #Drug safety #Pharmacovigilance

Quality overtakes cost as the priority for automating PV reporting

New research, involving 200 professionals in senior roles spanning pharmacovigilance (PV), Drug Safety and Product Safety departments, has found that quality has overtaken cost as a priority in plans for automating adverse event (AE) reporting. John Price, life sciences industry consultant and partner of Arriello, which commissioned this latest research, reports on the findings.  Although the Covid-19 pandemic has… Read More

#Editor's Choice #Exclusive Content #Intelligence #Market Reports #News #Opinion #Trends & Analysis

#Biotechnology #Pharma #Pharmacovigilance #Regulatory

Listicle: Experts on the differences between FDA and EMA regulations

Biotechs involved in drug discovery have to navigate increasingly complex regulatory environments across borders. Experienced experts and non-executive advisors to Arriello, Eric Caugant, Principal Consultant at Pharmacovigilance Systems Consulting & Board advisor to Arriello, and Judi Sills, JM Sills Consulting & Board advisor to Arriello, highlight the main differences between US… Read More

#Listicles #News #Sponsored Content #Videos

#Biotechnology #Pharma #Pharmacovigilance #Regulatory

FDA vs EMA: biotechs & the challenges of international pharmacovigilance

Biotechs involved in drug discovery have to navigate increasingly complex regulatory environments across borders. Experienced experts and non-executive advisors to Arriello, Eric Caugant in Paris and Judi Sills in New Jersey highlight the main differences between US and EU requirements, and advise on best preparations. Small biotech companies are commanding… Read More

#Editor's Choice #Exclusive Content #News #Regulatory

#CRO #Data #Pharma #Pharmacovigilance

Outsourcing clinical research support – time to put safety first

Increasingly, pharma companies are looking for a one-stop-shop when outsourcing clinical research support. Outsourcing without focusing on safety, however, is turning out to be a costly decision for some companies, leading to mistakes and budget overrun. Natalia Vlcek, Pharmacovigilance Manager and EU QPPV at Arriello Group, contends that it is… Read More

#Exclusive Content #News

#Marketing approval authorisation #Pharmacovigilance #Regulatory

Pharmacovigilance audits: implications of poor pass rates for drug developers

Vanessa Fachada Oliveira, Pharmacovigilance Manager & EU QPPV at Arriello, discusses 10 common issues identified in risk-based audits, and pinpoints implications for drug developers as well as marketing authorisation holders (MAHs). In EU markets, pharmacovigilance (PV) provisions are closely monitored to ensure that patients can have maximum confidence in the safety… Read More

#Exclusive Content #Regulatory